PORCINE SPLENIC PEPTIDES (POLYERGA) DECREASE THE NUMBER OF EXPERIMENTAL LUNG METASTASES IN MICE

Citation
M. Jurin et al., PORCINE SPLENIC PEPTIDES (POLYERGA) DECREASE THE NUMBER OF EXPERIMENTAL LUNG METASTASES IN MICE, Clinical & experimental metastasis, 14(1), 1996, pp. 55-60
Citations number
18
Categorie Soggetti
Oncology
ISSN journal
02620898
Volume
14
Issue
1
Year of publication
1996
Pages
55 - 60
Database
ISI
SICI code
0262-0898(1996)14:1<55:PSP(DT>2.0.ZU;2-5
Abstract
Preparations of splenic peptides under the name of Polyerga are being tested in numerous experimental immunomodulating and antitumorous mode ls and are also used during supportive treatment of tumorous patients, Further, the incidence of experimental lung metastases of melanoma ce lls in mice was significantly reduced if we used Polyerga preparations , The aim of our investigation was to determine whether Polyerga is ac tive directly against tumor cells or whether its activity is manifeste d by modulating immune and other possible abilities of the organism, T o clarify the problem glycopeptides containing Polyerga were incubated with melanoma B16F10 cells in vitro and the plating efficiency of the se cells determined when cultivated in medium, or in medium with diffe rent doses of the same Polyerga preparation, The cells preincubated in medium only reacted to the addition of increasing doses of Polyerga, 150 pg or more, by raising colonies number, However, 24-h incubation o f melanoma cells in the presence of 150 mu g of Polyerga per ml signif icantly reduced the number of tumor cell colonies in comparison to the corresponding cell cultures previously not exposed to Polyerga, These in vitro studies were extended to in vivo application using C57B1/GoZ gr mice injected i.v. with melanoma cells pretreated with Polyerga in vitro or previously not treated, A group of the treated mice was furth er injected i.p. with Polyerga, All the mice were killed at a particul ar time and the number of lung nodules determined, A significant diffe rence to the control values was noticed in each group that used Polyer ga, regardless of the exposure of melanoma cells to Polyerga in vitro, in vivo or to combined treatment, The efficiency of Polyerga applicat ion 7 days following i.v. injection of control melanoma cells (cultiva ted in medium only) when the nodules already exist, was further evalua ted in a combined treatment using DTIC, a drug of choice in melanomas, The smallest incidence of experimental lung metastases was observed i n the group exposed to the combination of DTIC and Polyerga, Polyerga preparation is thus active against melanoma cells, particularly in viv o and if combined with chemotherapy.